Your daughter got the job she wanted. She called from the parking lot, still shouting, and you said the right things in the right order.
Then you hung up and waited for it to land. Nothing came. Not relief, not pride. Just the same flatness you have been living in since spring.
Emotional numbness after trauma is one of the loneliest symptoms to carry. From the outside it looks like indifference. From the inside it looks like proof of something about your character.
It is neither. Numbing and detachment are recognized trauma symptoms that can outlast the fear-related ones. The panic can settle and the sleep can come back while this stays exactly where it was.
If you are in crisis or thinking about harming yourself, please do not wait. Call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7, or go to your nearest emergency room. Our Fort Worth office, 817-659-7344, is an outpatient practice and not a crisis line. If the numbness starts to shade into feeling that nothing matters, or into not wanting to be here, tell your clinician that day and call or text 988 if you cannot wait.
Is emotional numbness after trauma actually a symptom?
Yes. The Department of Veterans Affairs National Center for PTSD puts it in one sentence: “You may feel numb – unable to have positive or loving feelings toward other people – and lose interest in things you used to enjoy.” A federal health agency lists, as an ordinary feature of the condition, the thing you have been apologizing for.
It sits in the diagnostic criteria too. The same organization’s clinician page describes a cluster called negative alterations in cognitions and mood: decreased interest in activities, feeling isolated, difficulty experiencing positive affect. Our own PTSD service page says these symptoms can leave you feeling isolated and detached from family and friends. This is not a change in who you are. It belongs to the same condition as the nightmares.
Why did the fear improve while the feeling did not come back?
Trauma symptoms do not recover in a predictable sequence. The research supports something narrower.
In a 2019 study by Larsen, Fleming, and Resick in Psychological Trauma, 108 female rape survivors completed cognitive processing therapy or prolonged exposure. Overall symptoms improved; the ones most commonly still present at the end were distress at trauma reminders, detachment, and insomnia. That is one specific population.
A 2019 systematic review by Larsen and colleagues in the Journal of Anxiety Disorders pooled 51 randomized controlled trials, 68 treatment arms. Participants who completed PTSD treatment “continued to report residual PTSD symptoms: 31% reported clinical symptom levels, and 59% reported subthreshold levels at posttreatment, particularly within the hyperarousal cluster.” In those pooled arms the leftover burden concentrated in hyperarousal, not in numbing; which symptoms stay varies by person and by study.
Whether numbing lifts later than fear does is not something we know. It has not been studied well enough to say. A 2022 review by Vinograd and colleagues in Current Topics in Behavioral Neurosciences calls anhedonia “a relatively common, though understudied, feature of posttraumatic stress disorder (PTSD) that is not adequately targeted by existing treatments.” The flatness you describe is a known symptom, often still standing when treatment ends and studied far less than the louder parts of PTSD.
What the numbness does to the people at home
The VA’s page on how PTSD affects families names the pattern: when someone with PTSD avoids trauma reminders and feels emotionally numb, their partner is likelier to say the family is not functioning well, that intimacy is hard, and that they feel cut off and helpless.
It can change once it is said out loud. A partner who hears “I feel almost nothing right now, and it is a symptom I am working on” is in a different position from one left to conclude they are no longer loved. The VA points families toward couples-based and family therapy.
Is it the trauma, my depression, or my medication?
None of this sorts itself out from a web page.
Depression produces it. The National Center for PTSD notes that many depression symptoms overlap with PTSD, including not feeling pleasure or interest in things you used to enjoy. If depression is part of your picture, it deserves treatment of its own.
Dissociation is another: the numbness can come with watching yourself from outside, or the world looking unreal. The National Center for PTSD calls these depersonalization and derealization, and DSM-5 attaches them to PTSD as a specifier. Tell your clinician if it fits; it can change how treatment is sequenced.
Substances flatten emotion too. Alcohol, cannabis, and opioids all do it, and the DSM-5 criteria require a clinician to confirm symptoms “are not due to medication, substance use or other illness.”
Medication can contribute. About 46% of treated depressed patients reported emotional blunting in a 2017 survey of 669 people in the Journal of Affective Disorders, a self-report survey rather than a controlled trial. Goodwin and colleagues framed it as both a possible drug effect and a symptom of the illness itself.
In a 2022 survey of 752 patients in Annals of General Psychiatry, funded by H. Lundbeck A/S, 39% were considering stopping their antidepressant, or had already stopped, because of those effects. If that is you, bring it to your prescriber. The National Institute of Mental Health is explicit that people should not stop a prescribed medication without help from a health care provider, and that stopping too soon may cause harmful effects.
Flatness on an antidepressant is also a reason to re-check the diagnosis: unipolar depression, PTSD, bipolar disorder, or some combination. NIMH states that in bipolar disorder antidepressants “are not used alone because they can trigger a manic episode or rapid cycling.” Getting the diagnosis right changes the treatment, which is why nothing here is a reason to lower, switch, or stop anything on your own.
Where PRISM fits, and where it does not
PRISM is a GrayMatters Health device, FDA-cleared as an adjunctive treatment for PTSD in adults. You wear an EEG cap and watch an animated scene that responds to an amygdala-related signal from your EEG, while practicing self-regulation strategies aimed at settling it. What people experience varies.
Adjunctive is a regulatory word. The FDA clearance granted in March 2023 indicates it “as an adjunctive treatment of symptoms associated with posttraumatic stress disorder (PTSD) … together with other pharmacological and/or non-pharmacological interventions.” Alongside your therapy and your medication, never instead of either.
Numbing and detachment are symptoms associated with PTSD, so aiming an adjunctive treatment at them in someone who has PTSD sits inside the clearance. Aiming the device at anhedonia or depression without a PTSD diagnosis falls outside it. That use is off-label and investigational, and the published support is one open-label pilot with 34 completers training a different signal (Amital and colleagues, Brain Sciences, 2025).
The evidence behind the clearance was a prospective, single-arm, open-label trial of 79 subjects with no control group. Of those, 50.6% had an adverse event, the majority mild by the FDA summary’s account and commonly headache or fatigue; the two serious adverse events were judged unrelated to the device.
No trial of PRISM has used emotional numbness as its primary endpoint. A 2025 combined analysis of 128 patients from three trials of this neurofeedback approach (Goldental and colleagues, Journal of Clinical Medicine) reported improvement across all PTSD symptom clusters, including the one holding detachment. That is a reason to keep studying it, not evidence that the device treats numbness.
The June 2023 VA/DoD Clinical Practice Guideline strongly recommends the trauma-focused psychotherapies: cognitive processing therapy, EMDR, and prolonged exposure. It suggests written exposure therapy and present-centered therapy more weakly, and it places neurofeedback among the somatic therapies with insufficient evidence either way.
At our Fort Worth practice a typical PRISM course runs about 15 sessions over 6 to 8 weeks, with visits of roughly 45 minutes; the FDA summary describes 15 thirty-minute sessions, and the rest is setup and talking afterward. Our blog covers what a consultation looks like.
What to bring up at your next appointment
- The timeline: which symptoms changed, which did not, and when.
- Whether the numbness comes with feeling detached from your body, or the world seeming unreal.
- Every medication you take, plus any alcohol or other substance use.
Frequently asked questions
Does emotional numbness after trauma mean my treatment failed?
Not by itself. The VA’s National Center for PTSD describes feeling numb, and being unable to have loving feelings toward other people, as a symptom of PTSD. In a 2019 study of 108 women who completed cognitive processing therapy or prolonged exposure, detachment was among the symptoms most often still present.
Why do I feel detached from people I love?
Feeling isolated, decreased interest in activities, and difficulty experiencing positive affect all appear in the PTSD criteria under negative changes in thinking and mood, according to the National Center for PTSD. Feeling nothing toward your spouse or children is far more often a symptom of something treatable than a measure of your love for them.
Could my antidepressant be causing this?
Possibly, and research cannot cleanly separate a medication effect from the illness. In a 2017 survey of 669 treated depressed patients in the Journal of Affective Disorders, 46% reported emotional blunting, described by the authors as both a possible drug effect and a feature of depression. Take it to your prescriber, and change nothing on your own.
Can PRISM treat emotional numbness?
PRISM is FDA-cleared as an adjunctive treatment for symptoms associated with PTSD in adults, which covers the numbing and detachment symptoms named in the criteria. Using it for anhedonia or depression outside a PTSD diagnosis is off-label and investigational. No trial has used emotional numbness as a primary endpoint, and the June 2023 VA/DoD guideline puts neurofeedback among the therapies with insufficient evidence either way.
The bottom line
If the fear improved and the feeling did not come back, you have not failed at recovery. Numbing and detachment are named symptoms of PTSD, and in one study of women who finished trauma-focused therapy they were among the symptoms most often still present at the end. They also overlap with depression, dissociation, substance use, and medication-related blunting, which is why this belongs in front of a clinician who knows your history. PRISM is one option we can talk through: FDA-cleared as an adjunctive treatment for symptoms associated with PTSD in adults, used alongside therapy and medication, and off-label and investigational when aimed at anhedonia or depression outside a PTSD diagnosis.
Talk with us
If you are in Fort Worth or the surrounding North Texas area and what you have read here sounds familiar, we would be glad to talk it through with you. The Institute for Advanced Psychiatry is an outpatient practice at 6800 Harris Parkway, Suite 100, treating adults 18 and older. You can request an appointment or call 817-659-7344.
If you are in crisis or thinking about harming yourself, please do not wait for an appointment. Call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7, or go to your nearest emergency room.
Sources
- U.S. Department of Veterans Affairs, National Center for PTSD. “PTSD Basics.” Accessed 2026-09-02. https://www.ptsd.va.gov/understand/what/ptsd_basics.asp
- U.S. Department of Veterans Affairs, National Center for PTSD. “PTSD and DSM-5.” Accessed 2026-09-02. https://www.ptsd.va.gov/professional/treat/essentials/dsm5_ptsd.asp
- U.S. Department of Veterans Affairs, National Center for PTSD. “How Does PTSD Affect Families?” Accessed 2026-09-02. https://www.ptsd.va.gov/family/effect_families.asp
- U.S. Department of Veterans Affairs, National Center for PTSD. “Depression, Trauma, and PTSD.” Accessed 2026-09-02. https://www.ptsd.va.gov/understand/related/depression_trauma.asp
- Department of Veterans Affairs / Department of Defense. “VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder.” June 2023. https://www.healthquality.va.gov/guidelines/MH/ptsd/
- Larsen SE, Fleming CJE, Resick PA. “Residual symptoms following empirically supported treatment for PTSD.” Psychological Trauma: Theory, Research, Practice, and Policy 2019;11(2):207-215. https://doi.org/10.1037/tra0000384
- Larsen SE, Bellmore A, Gobin RL, Holens P, Lawrence KA, Pacella-LaBarbara ML. “An initial review of residual symptoms after empirically supported trauma-focused cognitive behavioral psychological treatment.” Journal of Anxiety Disorders 2019;63:26-35. https://doi.org/10.1016/j.janxdis.2019.01.008
- Vinograd M, Stout DM, Risbrough VB. “Anhedonia in Posttraumatic Stress Disorder: Prevalence, Phenotypes, and Neural Circuitry.” Current Topics in Behavioral Neurosciences 2022. https://doi.org/10.1007/7854_2021_292
- Goodwin GM, Price J, De Bodinat C, Laredo J. “Emotional blunting with antidepressant treatments: A survey among depressed patients.” Journal of Affective Disorders 2017. https://doi.org/10.1016/j.jad.2017.05.048
- Christensen MC, Ren H, Fagiolini A. “Emotional blunting in patients with depression. Part I: clinical characteristics.” Annals of General Psychiatry 2022. https://doi.org/10.1186/s12991-022-00387-1
- National Institute of Mental Health. “Mental Health Medications.” Accessed 2026-09-02. https://www.nimh.nih.gov/health/topics/mental-health-medications
- U.S. Food and Drug Administration, Center for Devices and Radiological Health. “510(k) Premarket Notification and 510(k) Summary, K222101 (Prism, GrayMatters Health Ltd.).” Decision date 2023-03-17. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K222101
- Goldental N, Gross R, Amital D, et al. “Amygdala EFP Neurofeedback Effects on PTSD Symptom Clusters and Emotional Regulation Processes.” Journal of Clinical Medicine 2025;14(7):2421. https://doi.org/10.3390/jcm14072421
- Amital D, et al. “Reward System EEG-fMRI-Pattern Neurofeedback for Major Depressive Disorder with Anhedonia: A Multicenter Pilot Study.” Brain Sciences 2025;15:476. https://doi.org/10.3390/brainsci15050476
- Institute for Advanced Psychiatry. “PRISM for PTSD.” Accessed 2026-09-02. https://www.psychiatryfortworth.com/services/prism/
- Institute for Advanced Psychiatry. “PTSD (Post-Traumatic Stress Disorder).” Accessed 2026-09-02. https://www.psychiatryfortworth.com/services/ptsd-post-traumatic-stress-disorder/
Medical disclaimer
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation for any individual. Reading it does not create a physician-patient relationship. Treatment decisions, including whether any medication or procedure is appropriate for you, should be made with a qualified clinician who knows your history. Do not start, stop, or change a psychiatric medication without talking to your prescriber. If you are experiencing a medical or mental health emergency, call 911 or 988.